A microcap biotech is getting a new identity — and $350 million to go with it.
Galera Therapeutics (OTC: GRTX) and privately-held Obsidian Therapeutics announced today they have entered into a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Obsidian Therapeutics and plans to trade on Nasdaq under the ticker symbol OBX.
For Galera shareholders, this is a lifeline. The stock was trading at less than five cents on the OTC markets heading into this announcement. For Obsidian, it’s a calculated path to the public markets — using Galera as a vehicle to access Nasdaq without a traditional IPO.
The Deal Structure
Under the merger agreement, Galera will merge into a subsidiary of the new parent company, Gazelle Parent, Inc., while Obsidian simultaneously merges into a separate subsidiary — with both surviving as wholly owned subsidiaries of the combined parent.
Concurrent with the merger, the companies secured commitments for a private placement financing expected to generate $350 million in gross proceeds. That’s a substantial war chest for a clinical-stage biotech, and signals serious institutional conviction in Obsidian’s pipeline.
The ownership breakdown tells the real story of who’s driving this combination: pre-merger equityholders of Obsidian are expected to own approximately 53.2% of the combined company, PIPE investors approximately 45%, and Galera’s legacy shareholders approximately 1.8%. Galera’s existing stockholders are essentially getting a small equity stake in a well-funded new entity rather than facing dissolution.
Who’s Backing It
Investors in the private placement include Balyasny Asset Management, Caligan Partners, Eventide Asset Management, Nantahala Capital, Octagon Capital, Redmile, Spruce Street Capital, and Trails Edge Capital Partners. That’s a roster of credible, healthcare-focused institutional names — not speculative money.
What Obsidian Actually Does
Obsidian focuses on engineered cell and gene therapies targeting unmet medical needs, while Galera had concentrated on treatments for radiation-induced toxicities. The combined company’s primary asset is OBX-115, a TIL (tumor-infiltrating lymphocyte) cell therapy. The company expects Phase 1 NSCLC data in the first half of 2027 and topline data from a melanoma registration-enabling trial by year-end 2027, supported by the merged company’s expanded cash runway.
TIL cell therapy is an emerging but compelling approach in oncology — it extracts a patient’s own immune cells from a tumor, engineers them, and reinfuses them to fight cancer. The space has attracted significant Big Pharma attention as cell therapy continues to mature beyond CAR-T into broader tumor types.
The Bigger Picture
This transaction is a textbook example of a structure the small-cap biotech world relies on — a reverse merger into a public shell paired with a concurrent PIPE to fund the surviving entity’s operations. It avoids the cost and volatility of a traditional IPO while still achieving a Nasdaq listing and fresh capital.
Closing requires approval from Galera and Obsidian stockholders, effectiveness of a Form S-4 registration statement, receipt of the approximately $350 million in private placement proceeds, and Nasdaq approval for the new parent’s listing.
For small-cap investors, the question now is whether OBX can justify that institutional confidence when the clinical data arrives in 2027.
